Contact this trialFirst, we need to learn more about you.
Monoclonal Antibody
Stem Cell Mobilization + Immunotherapy for Type 1 Diabetes
Recruiting1 awardPhase 1 & 2
Edmonton, Alberta
This trial is based on the "immunological reset" approach to treat type 1 diabetes. T-depletion therapy and anti-inflammatory treatment will restore self-tolerance in T1DM patients. Autologous, peripheral-blood mobilized hematopoietic CD34+-enriched stem cells and a long-acting GLP-1 analogue will promote pancreatic islet regeneration and repair.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.